Barclays
AUPH icon

Barclays’s Aurinia Pharmaceuticals AUPH Stock Holding History

Barclays’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-42,500
Closed -$213K – 4862
2024
Q1 		$213K Buy
42,500
+9,500
+29% +$64.4K ﹤0.01% 4086
2023
Q4 		$297K Buy
+33,000
New +$272K ﹤0.01% 4212
2022
Q1 		– Sell
-62,500
Closed -$1.43M – 4938
2021
Q4 		$1.43M Buy
+62,500
New +$1.48M ﹤0.01% 2591
2019
Q1 		– Sell
-50,000
Closed -$341K – 6992
2018
Q4 		$341K Hold
50,000
– – ﹤0.01% 4167
2018
Q3 		$332K Buy
+50,000
New +$280K ﹤0.01% 4599

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's AUPH Position: Q2 2026 in Review

Barclays reduced its Aurinia Pharmaceuticals (AUPH) stake by 7% in Q2 2026, selling an estimated $33.7K and leaving 27,892 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #3263.

Barclays first reported a position in AUPH in Q2 2017 and has held it in 34 quarters since. The position peaked at $13.2M in Q3 2021. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Barclays held 27,892 shares of Aurinia Pharmaceuticals worth $473K as of Q2 2026.
  • Barclays sold 2,108 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3263 holding.
  • Barclays first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 34 quarters since.
  • Barclays's Aurinia Pharmaceuticals position peaked at $13.2M in Q3 2021.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.